Publications by authors named "Naoko Tomimatsu"
Article Synopsis
- In Japan, a study was conducted on the safety and efficacy of ligelizumab, an anti-IgE monoclonal antibody, for treating chronic spontaneous urticaria (CSU) in patients who weren't responding well to H1-antihistamines.
- The study, which included 66 adult participants, showed that while 80.3% experienced mild to moderate side effects, there were no severe adverse events or anaphylaxis, and only 6.1% stopped treatment due to side effects.
- Significant improvements were noted: UAS7 scores improved quickly by Week 4 and continued to improve by Week 52, with 50% of patients achieving no symptoms, and a notable increase in quality of life
Inclisiran sodium (Brand name: LEQVIO for s.c. injection syringe 300 mg, hereinafter referred to as inclisiran), a small interfering ribonucleic acid (siRNA) product that targets the mRNA that encodes the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein was approved on September 25, 2023 for the indication of "Familial hypercholesterolemia, hypercholesterolemia" in Japan.
View Article and Find Full Text PDFPituitary adenylate cyclase-activating polypeptide (PACAP) has been shown to be neurotrophic or neuroprotective in various neurons in culture. It is expressed in spinal motoneurons in vivo and its expression is increased markedly after axotomy, suggesting a neuroprotective role via an autocrine mechanism. However, neurotrophic activity of PACAP has not been reported for motoneurons.
View Article and Find Full Text PDFAmyotrophic lateral sclerosis (ALS) is a progressive motoneuron disease, whose pathogenesis remains unclear. Phorbol 12-myristate 13-acetate (PMA) has been shown to be neurotrophic and neuroprotective in several types of neurons in culture. However, the survival effect of PMA on motoneurons has not been reported.
View Article and Find Full Text PDF